Table 3.

Summary of immunogenicity test results from 4 clinical studies.

	NCT02937116	NCT03114683	NCT03116152	NCT03150875
	Ia+Ib	II	II	III
	Solid Tumors	cHL	EC	Sq NSCLC	All studies
N (%)	(N = 206)	(N = 95)	(N = 49)	(N = 31)	(N = 381)
Treatment emergent ADA+	1 (1/206, 0.49)	1 (1/95, 1.05)	0	0	2 (2/381, 0.52)
Treatment emergent NAb+	0	1 (1/95, 1.05)	0	0	1 (1/381, 0.26)
Baseline ADA+	14 (14/206, 6.80)	6 (6/87, 6.90)	2 (2/49, 4.08)	2 (2/31, 6.45)	24 (24/381, 6.30)